A recent report issued by market research firm Grand View Research Inc., released in February, projected the global market for Medicinal Cannabis products to reach USD 55.8 billion by 2025.[1]
SCU's potential entry into the Medicinal Cannabis market is in addition to the Company's established Dendrobium Officinale Kimura et Migo orchid ("Dendrobium") stem cell extract product lines.
These Dendrobium extract products can be used across a vast array of products, including anti-aging creams, hair care, Traditional Chinese Medicines, dietary supplements, foods and beverages.
Through its Dendrobium business, SCU has pioneered the use of a range of cutting-edge fingerprint mapping technologies such as High Performance Liquid Chromatography (HPLC) to establish the authenticity of raw materials, test for active constituents and ensure their potency.
SCU anticipates that strong synergies with the existing Dendrobium business, including the ability to leverage existing technologies and investments, will give the Company a significant competitive advantage as it enters the highly lucrative Medicinal Cannabis market.
Jamie Khoo added: "Medicinal Cannabis has been called a wonder drug by numerous leading health experts, and we anticipate the industry is set for tremendous growth over the coming years.
"SCU is uniquely placed in terms of technology and expertise to advance in the Medicinal Cannabis market over the coming years."
A recent report issued by market research firm Grand View...
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
